PLEASANTON, Calif., Jan. 8, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Peter Gassner, founder and CEO, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 2:15 p.m. PT in San Francisco.
The presentation will be webcast. Links to the live and archived webcast will be available on Veeva's investor relations website at https://ir.veeva.com.
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
Veeva uses its ir.veeva.com website as a means of disclosing material non-public information, announcing upcoming investor conferences, and for complying with its disclosure obligations under Regulation FD. Accordingly, you should monitor Veeva's investor relations website in addition to following its press releases, SEC filings, and public conference calls and webcasts.
Investor Relations Contact:
Gunnar Hansen
Veeva Systems Inc.
267-460-5839
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Maria Scurry
Veeva Systems Inc.
781-366-7617
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$215.89 |
Daily Change: | 0.58 0.27 |
Daily Volume: | 767,168 |
Market Cap: | US$34.900B |
September 05, 2024 September 05, 2024 August 28, 2024 August 22, 2024 August 13, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB